schliessen

Filtern

 

Bibliotheken

Correlation of plasma catestatin level and the prognosis of patients with acute myocardial infarction

Catestatin is a peptide which is a potent inhibitor of catecholamine secretion and played essential functions in the cardiovascular system. Previous research found that dramatic changes of catestatin were associated with hemodynamics in acute myocardial infarction (AMI) during the first week after t... Full description

Journal Title: PLoS ONE 01 January 2015, Vol.10(4), p.e0122993
Main Author: Dan Zhu
Other Authors: Hong Xie , Xinyu Wang , Ying Liang , Haiyi Yu , Wei Gao
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0122993
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: doaj_soai_doaj_org_article_21912af30e274f28a5eef25fb9c6e077
title: Correlation of plasma catestatin level and the prognosis of patients with acute myocardial infarction
format: Article
creator:
  • Dan Zhu
  • Hong Xie
  • Xinyu Wang
  • Ying Liang
  • Haiyi Yu
  • Wei Gao
subjects:
  • Sciences (General)
ispartof: PLoS ONE, 01 January 2015, Vol.10(4), p.e0122993
description: Catestatin is a peptide which is a potent inhibitor of catecholamine secretion and played essential functions in the cardiovascular system. Previous research found that dramatic changes of catestatin were associated with hemodynamics in acute myocardial infarction (AMI) during the first week after the AMI symptoms onset, but whether catestatin is also involved in the pathophysiological progression after AMI and then a predictor for outcomes is not clear. The aim of this study is to determine the correlation of plasma catestatin levels at different time points and the prognosis of AMI. 100 participants recruited were all patients with AMI, all of who received successful primary percutaneous coronary intervention (PCI) within 12h from the AMI symptom onset in our center; the concentrations of plasma catestatin were evaluated from blood samples of those 100 participants. Subsequent 65 months' follow-up was performed after discharging to evaluate cardiac adverse events and the association between catestatin levels and prognosis of AMI was examined. We confirmed the dramatic change of catestatin concentrations in the first week of AMI, and the levels of catestatin on D3 were much higher in adverse events group than those in non-adverse events group (p
language: eng
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0122993
fulltext: fulltext_linktorsrc
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID399427280
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidoai_doaj_org_article_21912af30e274f28a5eef25fb9c6e077
sourceiddoaj_s
recordidTN_doaj_soai_doaj_org_article_21912af30e274f28a5eef25fb9c6e077
sourcesystemOther
dbidDOA
pqid1671014276
galeid429778573
display
typearticle
titleCorrelation of plasma catestatin level and the prognosis of patients with acute myocardial infarction
creatorDan Zhu ; Hong Xie ; Xinyu Wang ; Ying Liang ; Haiyi Yu ; Wei Gao
ispartofPLoS ONE, 01 January 2015, Vol.10(4), p.e0122993
identifierE-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0122993
subjectSciences (General)
descriptionCatestatin is a peptide which is a potent inhibitor of catecholamine secretion and played essential functions in the cardiovascular system. Previous research found that dramatic changes of catestatin were associated with hemodynamics in acute myocardial infarction (AMI) during the first week after the AMI symptoms onset, but whether catestatin is also involved in the pathophysiological progression after AMI and then a predictor for outcomes is not clear. The aim of this study is to determine the correlation of plasma catestatin levels at different time points and the prognosis of AMI. 100 participants recruited were all patients with AMI, all of who received successful primary percutaneous coronary intervention (PCI) within 12h from the AMI symptom onset in our center; the concentrations of plasma catestatin were evaluated from blood samples of those 100 participants. Subsequent 65 months' follow-up was performed after discharging to evaluate cardiac adverse events and the association between catestatin levels and prognosis of AMI was examined. We confirmed the dramatic change of catestatin concentrations in the first week of AMI, and the levels of catestatin on D3 were much higher in adverse events group than those in non-adverse events group (p<0.0001), but the ratio of D7/D3 was significantly lower. In addition, the Kaplan-Meier analysis showed that the groups in which the levels on D3 were higher (p<0.0001) and the ratios of D7/D3 were lower (p<0.0001), patients trended to be more susceptive to adverse events after AMI. Furthermore, according to the analysis, we surmised catestatin level on D3 as an appropriate predictor for outcomes in patients with AMI with good specificity as well as sensitivity. All of the evidence confirmed that catestatin plays an important role in the progress of AMI, and may act as a promising target for prognostic prediction.
languageeng
oafree_for_read
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttps://doaj.org/article/21912af30e274f28a5eef25fb9c6e077$$EView_full_text_in_DOAJ
search
creatorcontrib
0Dan Zhu
1Hong Xie
2Xinyu Wang
3Ying Liang
4Haiyi Yu
5Wei Gao
titleCorrelation of plasma catestatin level and the prognosis of patients with acute myocardial infarction
description

Catestatin is a peptide which is a potent inhibitor of catecholamine secretion and played essential functions in the cardiovascular system. Previous research found that dramatic changes of catestatin were associated with hemodynamics in acute myocardial infarction (AMI) during the first week after the AMI symptoms onset, but whether catestatin is also involved in the pathophysiological progression after AMI and then a predictor for outcomes is not clear. The aim of this study is to determine the correlation of plasma catestatin levels at different time points and the prognosis of AMI. 100 participants recruited were all patients with AMI, all of who received successful primary percutaneous coronary intervention (PCI) within 12h from the AMI symptom onset in our center; the concentrations of plasma catestatin were evaluated from blood samples of those 100 participants. Subsequent 65 months' follow-up was performed after discharging to evaluate cardiac adverse events and the association between catestatin levels and prognosis of AMI was examined. We confirmed the dramatic change of catestatin concentrations in the first week of AMI, and the levels of catestatin on D3 were much higher in adverse events group than those in non-adverse events group (p<0.0001), but the ratio of D7/D3 was significantly lower. In addition, the Kaplan-Meier analysis showed that the groups in which the levels on D3 were higher (p<0.0001) and the ratios of D7/D3 were lower (p<0.0001), patients trended to be more susceptive to adverse events after AMI. Furthermore, according to the analysis, we surmised catestatin level on D3 as an appropriate predictor for outcomes in patients with AMI with good specificity as well as sensitivity. All of the evidence confirmed that catestatin plays an important role in the progress of AMI, and may act as a promising target for prognostic prediction.

subjectSciences (General)
general
0English
1Public Library of Science (PLoS)
210.1371/journal.pone.0122993
3Directory of Open Access Journals (DOAJ)
sourceiddoaj_s
recordiddoaj_soai_doaj_org_article_21912af30e274f28a5eef25fb9c6e077
issn
01932-6203
119326203
rsrctypearticle
creationdate2015
addtitlePLoS ONE
searchscope
0doaj_full
1doaj1
scope
0doaj_full
1doaj1
lsr45$$EView_full_text_in_DOAJ
tmp01Directory of Open Access Journals (DOAJ)
tmp02DOA
startdate20150101
enddate20150101
lsr40PLoS ONE, 01 January 2015, Vol.10 (4), p.e0122993
doi10.1371/journal.pone.0122993
citationpf e0122993 vol 10 issue 4
lsr30VSR-Enriched:[galeid, pages, pqid]
sort
titleCorrelation of plasma catestatin level and the prognosis of patients with acute myocardial infarction
authorDan Zhu ; Hong Xie ; Xinyu Wang ; Ying Liang ; Haiyi Yu ; Wei Gao
creationdate20150101
lso0120150101
facets
frbrgroupid5810875561106153532
frbrtype5
newrecords20190714
languageeng
topicSciences (General)
collectionDirectory of Open Access Journals (DOAJ)
prefilterarticles
rsrctypearticles
creatorcontrib
0Dan Zhu
1Hong Xie
2Xinyu Wang
3Ying Liang
4Haiyi Yu
5Wei Gao
jtitlePLoS ONE
creationdate2015
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
au
0Dan Zhu
1Hong Xie
2Xinyu Wang
3Ying Liang
4Haiyi Yu
5Wei Gao
atitleCorrelation of plasma catestatin level and the prognosis of patients with acute myocardial infarction
jtitlePLoS ONE
risdate20150101
volume10
issue4
spagee0122993
eissn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstract

Catestatin is a peptide which is a potent inhibitor of catecholamine secretion and played essential functions in the cardiovascular system. Previous research found that dramatic changes of catestatin were associated with hemodynamics in acute myocardial infarction (AMI) during the first week after the AMI symptoms onset, but whether catestatin is also involved in the pathophysiological progression after AMI and then a predictor for outcomes is not clear. The aim of this study is to determine the correlation of plasma catestatin levels at different time points and the prognosis of AMI. 100 participants recruited were all patients with AMI, all of who received successful primary percutaneous coronary intervention (PCI) within 12h from the AMI symptom onset in our center; the concentrations of plasma catestatin were evaluated from blood samples of those 100 participants. Subsequent 65 months' follow-up was performed after discharging to evaluate cardiac adverse events and the association between catestatin levels and prognosis of AMI was examined. We confirmed the dramatic change of catestatin concentrations in the first week of AMI, and the levels of catestatin on D3 were much higher in adverse events group than those in non-adverse events group (p<0.0001), but the ratio of D7/D3 was significantly lower. In addition, the Kaplan-Meier analysis showed that the groups in which the levels on D3 were higher (p<0.0001) and the ratios of D7/D3 were lower (p<0.0001), patients trended to be more susceptive to adverse events after AMI. Furthermore, according to the analysis, we surmised catestatin level on D3 as an appropriate predictor for outcomes in patients with AMI with good specificity as well as sensitivity. All of the evidence confirmed that catestatin plays an important role in the progress of AMI, and may act as a promising target for prognostic prediction.

pubPublic Library of Science (PLoS)
doi10.1371/journal.pone.0122993
urlhttps://doaj.org/article/21912af30e274f28a5eef25fb9c6e077
lad01PLoS ONE
oafree_for_read
pagese0122993
date2015-01-01